LucentAD Complete
Comprehensive blood-based biomarker panel for assessing Alzheimer's pathology
Software · OtherCompany source
Company profile
About Lucent Diagnostics
Lucent Diagnostics is a Quanterix brand pioneering ultra-sensitive, blood-based biomarker testing for Alzheimer's disease. Using proprietary Simoa® (Single Molecule Array) technology, the company enables detection of Alzheimer's-related biomarkers in blood with unprecedented sensitivity—1000 times more sensitive than traditional automated immunoassay analyzers. The company's flagship products, LucentAD® Complete and LucentAD® p-Tau217, provide comprehensive biomarker panels for assessing Alzheimer's pathology before symptoms progress. These tests offer a non-invasive alternative to cerebrospinal fluid (CSF) analysis and PET imaging, making Alzheimer's risk assessment more accessible to patients and providers. Lucent Diagnostics operates as a CLIA-certified laboratory and serves healthcare providers, diagnostic laboratories, research organizations, clinical trial sponsors, and pharmaceutical companies. The company's mission is to transform Alzheimer's detection and diagnosis through cutting-edge biomarker testing, making highly-sensitive, accessible blood tests the new standard of care. By enabling earlier identification of disease-related changes long before symptoms appear, Lucent Diagnostics empowers providers to improve patient care and outcomes in the fight against Alzheimer's disease.
Company description Lucent Diagnostics official website
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Lucent Diagnostics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Alzheimer's disease
- amyloid pathology
- cognitive impairment
- neurodegenerative diseases
- tau pathology
Who it serves
- Biotech Companies
- Clinical Trial Sponsors
- CROs
- Diagnostic Laboratories
- Healthcare Providers
- Pharma Companies
- Research Organizations
- Universities
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsEurope · Global (through distributor partners) · North America
Company sourceOfficial website
Company milestones
Platform expansion
Launched LucentAD® p-Tau 217 test for high accuracy detection of amyloid pathology. Launched LucentAD® Complete multi-analyte blood test. Participating in AAIC 2025. FDA full approval of Eisai and Biogen's Leqembi treatment created market opportunity for blood-based testing.
Partnerships
Recorded partners
- Biogen
- Eisai
- Quanterix (parent company)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
LucentAD p-Tau 217
Highly specific blood test identifying Alzheimer's pathology before symptoms progress
Software · OtherCompany source
Simoa Technology Platform
Ultra-sensitive single-molecule biomarker detection platform for neurological diseases
Platform · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
No linked records are currently available.
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
1000x more sensitive than traditional immunoassay
biomarker detection sensitivity
femtogram-level detection
biomarker concentration measurement
high diagnostic accuracy
Alzheimer's risk assessment
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Lucent Diagnostics
Recent articles published on Lucent Diagnostics's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.